Vulvar and Vaginal Atrophy Therapy Market Trends

  • Report ID: 4178
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Vulvar and Vaginal Atrophy Therapy Market Trends

Growth Drivers

  • Increasing Female Geriatric Population - According to the United Nations Department of Economic and Social Affairs, World Population Ageing 2020 Highlights report, there is a rapid growth of the aging population. An estimated 727 million people are aged 65 or more in 2020. The number is forecasted to reach over 1.5 billion people, almost more than double from 9.3% in 2020 to 16% in 2050. According to the data, on average, women live longer than men. The total aging population comprises 55% of the female population aged 65 years and above.

  • Increasing Incidences of Breast Cancer and Uterine Cancer in Women - Breast cancer has been found to affect the body’s hormones. In women, about 67%-80% of breast cancer cases are estrogen receptor (ER) positive, while in men, around 90% and 80% are estrogen receptor (ER) and progesterone receptor (PR) positive, respectively. According to the World Health Organization (WHO), in 2020, 2.3 million women were diagnosed with breast cancer worldwide. On the other hand, according to the National Cancer Institute, as of 2022, uterine cancer represents 3.4% of all new cancer cases in the United States.

  • Growing Healthcare Expenditure - According to the Centers for Medicare & Medicaid Services, national health spending in the United States is expected to grow at a 5.5 percent annual rate, reaching approximately USD 6.0 trillion by the end of 2027.

  • Increasing Lifestyle-Related Diseases in Women- Lifestyle diseases, associated with physical inactivity and poor diet quality, pose a significant health burden. Gestational diabetes mellitus (GDM), type 2 diabetes (DM2), and polycystic ovary syndrome (PCOS) are a few of the lifestyle-related diseases that affect women. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (up to 5 million) of US women of reproductive age as of 2020. Certain lifestyle disorders, such as depression, insomnia, and weight gain, are also common among women.

  • Growing Prevalence of UTI – The prevalence of UTI is very higher and a considerable number of women across the globe aren’t aware of it. It is estimated that, in every 25 women, 10 of them suffer from urinary tract infections.

Challenges

  • Unreported Cases of Genitourinary Syndrome of Menopause Owing to a Lack of Awareness - A significant number of women aren’t aware of this therapy. In the rural areas of most developing countries, women have no awareness of even UTI, and the burning sensation is very high. Women give no particular attention to these diseases since many of them hesitate to elaborate on the symptoms. Hence, such hesitance and lack of awareness are estimated to limit the market growth over the forecast period.
  • Concerns about Vulvar and Vaginal Atrophy from Cancer Combination Treatments
  • Adverse Effect on the Quality of Life

Vulvar And Vaginal Atrophy (Vva) Therapy Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~11%

Base Year Market Size (2022)

~ USD 2 Billion

Forecast Year Market Size (2035)

~ USD 5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Base Year

2024

Forecast Year

2025-2037

CAGR

10.7%

Base Year Market Size (2024)

USD 2.46 billion

Forecast Year Market Size (2037)

USD 9.22 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4178
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of vulvar and vaginal atrophy therapy is assessed at USD 2.9 billion.

The vulvar and vaginal atrophy therapy market size was over USD 2.46 billion in 2024 and is projected to reach USD 9.22 billion by 2037, growing at around 10.7% CAGR during the forecast period i.e., between 2025-2037. Increasing incidences of breast cancer and uterine cancer in women and the growing prevalence of UTI will boost the market growth.

North America industry is poised to hold largest revenue share by 2037, attributed to surge in the number of women suffering from pre and postmenopausal hormonal imbalances along with the growing number of vaginal cancer cases in the region.

The major players in the market are Daré Bioscience, Inc., Almirall, S.A., Viveve, Inc., Lutronic Corporation, Venus Concept, ThermiGen, LLC, Alma Lasers LTD., BTL, Fotona d.o.o., TherapeuticsMD, Inc, .
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample